Activity of pleconaril against enteroviruses

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 9, 1999, Pages 2109-2115

  Pevear, Daniel C ^a   Tull, Tina M ^a   Seipel, Martin E ^a   Groarke, James M ^a  

^a ViroPharma Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PLECONARIL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MECHANISM; ENTEROVIRUS; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PREVALENCE; PRIORITY JOURNAL; SEROTYPING; STRAIN DIFFERENCE; VIRUS INHIBITION;

EID: 0032850143     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.9.2109     Document Type: Article

References (55)

1. Abdel-Rahman, S. M., and G. L. Kearns. 1999. Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults. J. Clin. Pharmacol. 39:613-618.
2. Abzug, M. J., M. J. Levin, and H. A. Rotbart. 1993. Profile of enterovirus disease in the first two weeks of life. Pediatr. Infect. Dis. J. 12:820-824.
3. Abzug, M. J. 1995. Perinatal enterovirus infections, p. 221-238. In H. A. Rotbart (ed.), Human enterovirus infections. ASM Press, Washington, D.C.
4. Badger, J., I. Minor, M. J. Kremer, M. A. Oliveira, T. J. Smith, J. P. Griffith, D. M. A. Guerin, S. Krishnaswamy, M. Luo, M. G. Rossmann, M. A. McKinlay, G. D. Diana, F. J. Dutko, M. Fancher, R. R. Rueckert, and B. A. Heinz. 1988. Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc. Natl. Acad. Sci. USA 85:3304-3308.
5. Bailey, T. R., G. D. Diana, P. F. Kowalczyk, V. Akullian, M. A. Eissenstat, D. Cutliffe, J. P. Mallamo, P. M. Carabateas, and D. C. Pevear. 1992. Antirhinoviral activity of heterocyclic analogs of Win 54954. J. Med. Chem. 35: 4628-4633.
6. Centers for Disease Control. 1981. Enterovirus surveillance report, 1970-1979, Centers for Disease Control, Atlanta, Ga.
7. Chidekel, A. S., C. L. Rosen, and A. R. Buzzy. 1997. Rhinovirus infection associated with serious lower respiratory illness in patients with bronchopulmonary dysplasia. Pediatric Infect. Dis. J. 16:43-47.
8. Chonmaitree, T., and L. Mann. 1995. Respiratory infections, p. 255-270. In H. A. Rotbart (ed.), Human enterovirus infections. ASM Press, Washington, D.C.
9. Diana, G. D., A. M. Treasurywala, T. R. Bailey, R. C. Oglesby, D. C. Pevear, and F. J. Dutko. 1990. A model for compounds active against human rhinovirus-14 based on X-ray crystallography data. J. Med. Chem. 33:1306-1311.
10. Diana, G. D., P. Kowalczyk, A. M. Treasurywala, R. C. Oglesby, D. C. Pevear, and F. J. Dutko. 1992. CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14. J. Med. Chem. 35:1002-1008.
11. Diana, G. D., D. Cutcliffe, D. L. Volkots, J. P. Mallamo, T. R. Bailey, N. Vescio, R. C. Oglesby, T. J. Nitz, J. Wetzel, V. Giranda, D. C. Pevear, and F. J. Dutko. 1993. Antipicornavirus activity of tetrazole analogues related to disoxaril. J. Med. Chem. 36:3240-3250.
12. Diana, G. D., D. L. Volkots, T. J. Nitz, T. R. Bailey, M. A. Long, N. Vescio, S. Aldous, D. C. Pevear, and F. J. Dutko. 1994. Oxadiazoles as ester bioisosteric replacements in compounds related to disoxaril. Antirhinovirus activity. J. Med. Chem. 37:2421-2436.
13. Diana, G. D., P. Rudewicz, D. C. Pevear, T. J. Nitz, S. C. Aldous, D. J. Aldous, D. T. Robinson, T. Draper, F. J. Dutko, C. Aldi, G. Gendron, R. C. Oglesby, D. L. Volkots, M. Reuman, T. R. Bailey, R. Czerniak, T. Block, R. Roland, and J. Oppermann. 1995. Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. J. Med. Chem. 38:1355-1371.
14. Diana, G. D., and D. C. Pevear. 1997. Antipicornavirus drugs: current status. Antivir. Chem. Chemother. 8:401-408.
15. Gauntt, C. J., M. D. Trousdale, D. R. LaBadie, R. E. Paque, and T. Nealon. 1979. Properties of coxsackievirus B3 variants which are amyocarditic or myocarditic for mice. J. Med. Virol. 3:207-220.
16. Groarke, J. M., and D. C. Pevear. 1999. Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants. J. Infect. Dis. 179:1538-1541.
17. Guiles, J. W., G. D. Diana, and D. C. Pevear. 1995. [(Biaryloxy)alkyl]isoxazoles: picornavirus inhibitors. J. Med. Chem. 38:2780-2783.
18. Hadfield, A. T., W.-M. Lee, R. Zhao, M. A. Oliveira, I. Minor, R. R. Rueckert, and M. G. Rossmann. 1997. The refined structure of human rhinovirus 16 at 2.15 Å resolution: implications for the viral life cycle. Structure 5:427-441.
19. Halonen, P., E. Rocha, J. Hierholzer, B. Holloway, T. Hyypia, P. Hurskainen, and M. Pallansch. 1995. Detection of enteroviruses and rhinoviruses in clinical specimens by PCR and liquid-phase hybridization. J. Clin. Microbiol. 33:648-653.
20. Jaeger, E. P., D. C. Pevear, P. J. Felock, G. R. Russo, and A. M. Treasurywala. 1995. Genetic algorithm based method to design a primary screen for antirhinovirus agents, p. 139-155. In C. H. Reynolds, M. K. Holloway, and H. K. Cox (ed.), Computer-aided molecular design: applications in agro-chemicals, materials, and pharmaceuticals. American Chemical Society, Washington, D.C.
21. Kenny, M. T., J. K. Dulworth, T. M. Barger, and J. K. Daniel. 1987. Antipicornavirus activity of some diaryl methanes and aralkylaminopyridines. Antivir. Res. 7:87-97.
22. Kim, J. O., and R. L. Hodinka. 1998. Serious respiratory illness associated with rhinovirus infection in a pediatric population. Clin. Diagn. Virol. 10: 57-65.
23. Kim, K. H., P. Willingmann, Z. X. Gong, M. J. Kremer, M. S. Chapman, I. Minor, M. A. Oliveira, M. G. Rossmann, K. Andries, G. D. Diana, F. J. Dutko, M. A. McKinlay, and D. C. Pevear. 1993. A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A. J. Mol. Biol. 230:206-227.
24. Kim, S., T. J. Smith, M. S. Chapman, M. G. Rossmann, D. C. Pevear, F. J. Dutko, P. J. Felock, G. D. Diana, and M. A. McKinlay. 1989. Crystal structure of human rhinovirus serotype 1A (HRV1A). J. Mol. Biol. 210:91-111.
25. Lewis, J. K., B. Bothner, T. J. Smith, and G. Siuzdak. 1998. Antiviral agent blocks breathing of the common cold virus. Proc. Natl. Acad. Sci. USA 95: 6774-6778.
26. Mallamo, J. P., G. D. Diana, D. C. Pevear, F. J. Dutko, M. S. Chapman, K. H. Kim, I. Minor, M. Oliveira, and M. G. Rossmann. 1992. Conformationally restricted analogues of disoxaril: a comparison of the activity against human rhinovirus types 14 and 1A. J. Med. Chem. 35:4690-4695.
27. McKinlay, M. A., F. J. Dutko, D. C. Pevear, M. G. Woods, G. D. Diana, and M. G. Rossmann. 1990. Rational design of antipicornavirus agents, p. 366-372. In M. A. Brinton and F. X. Heinz (ed.), New aspects of positive-strand RNA viruses. American Society for Microbiology, Washington, D.C.
28. McKinlay, M. A., and D. C. Pevear. 1992. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu. Rev. Microbiol. 46:635-654.
29. McKinlay, M. A. Personal communication.
30. McKinney, R. E. Jr., S. L. Katz, and C. M. Wilfert. 1987. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev. Infect. Dis. 9: 334-356.
31. Melnick, J. L. 1996. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p. 655-712. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
32. Modlin, J. F. 1986. Perinatal echovirus infection: insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries. Rev. Infect. Dis. 8:918-926.
33. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63.
34. Muckelbauer, J. K., M. Kremer, I. Minor, G. Diana, F. J. Dutko, J. Groarke, D. C. Pevear, and M. G. Rossmann. 1995. The structure of coxsackievirus B3 at 3.5 Å resolution. Structure 3:653-667.
35. Muir, P., U. Kammerer, K. Korn, M. N. Mulders, T. Poyry, B. Weissbrich, R. Kandolf, G. M. Cleator, and A. M. van Loon. 1998. Molecular typing of enteroviruses: current Status and future requirements. Clin. Microbiol. Rev. 11:202-227.
36. National Institute of Allergy and Infectious Diseases. 1998. Common cold fact sheet. National Institutes of Health, Bethesda, Md.
37. National Institutes of Health. 1988. Guide for the care and use of laboratory animals. National Institutes of Health, Bethesda, Md.
38. Otto, M. J., M. P. Fox, M. J. Fancher, M. F. Kuhrt, G. D. Diana, and M. A. McKinlay. 1985. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 27:883-886.
39. Pevear, D. C., E. M. Jaeger, and T. M. Tull. Activity of pleconaril against rhinoviruses. Submitted for publication.
40. Pevear, D. C., M. J. Fancher, P. J. Felock, M. G. Rossmann, M. S. Miller, G. Diana, A. M. Treasurywala, M. A. McKinlay, and F. J. Dutko. 1989. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J. Virol. 63:2002-2007.
41. Pevear, D. C., M. E. Seipel, M. Pallansch, and M. A. McKinlay. 1996. In vitro activity of VP 63843 against field isolates of non-polio enteroviruses, abstr. H99, p. 181. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
42. Phelps, D. K., and C. B. Post. 1995. A novel basis for capsid stabilization by antiviral compounds. J. Mol. Biol. 254:544-551.
43. Phelps, D. K., P. J. Rossky, and C. B. Post. 1998. Influence of an antiviral compound on the temperature dependence of viral protein flexibility and packing: a molecular dynamics study. J. Mol. Biol. 276:331-337.
44. Rewers, M., and M. Atkinson. 1995. The possible role of enteroviruses in diabetes mellitus, p. 353-385. In H. A. Rotbart (ed.), Human enterovirus infections. ASM Press, Washington, D.C.
45. Rotbart, H. A. 1995. Meningitis and encephalitis, p. 271-289. In H. A. Rotbart (ed.), Human enterovirus infections. ASM Press, Washington, D.C.
46. Rotbart, H. A., A. Jones, V. Novelli, S. Blanche, and A. D. B. Webster. 1997. Pleconaril treatment of chronic enteroviral central nervous system infections in children with agammaglobulinemia, abstr. H-126, p. 236. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
47. Rotbart, H. A., and the Pleconaril Treatment Registry. 1998. Pleconaril therapy of potentially life-threatening enterovirus infections, abstr. 791, p. 249. In Abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America.
48. Rudge, P., A. D. Webster, T. Revesz, T. Warner, T. Espanol, C. Cunningham-Rundles, and N. Hyman. 1996. Encephalomyelitis in primary hypogammaglobulinaemia. Brain 119:1-15.
49. Schif, G. M., M. A. McKinlay, and J. R. Sherwood. 1996. Oral efficacy of VP 63843 in coxsackievirus A21 infected volunteers, abstr. H-43, p. 171. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
50. Scott Levin. 1997. Physician drug & diagnosis audit. Scott-Levin, a Division of PMSI Scott-Levin, Inc., Newtown, Pa.
51. Smith, T. J., M. J. Kremer, M. Luo, G. Vriend, E. Arnold, G. Kamer, M. G. Rossmann, M. A. McKinlay, G. D. Diana, and M. J. Otto. 1986. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 233:1286-1293.
52. Strikas, R. A., L. J. Anderson, and R. A. Parker. 1986. Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States, 1970-1983. J. Infect. Dis. 153:346-351.
53. Tull, T. M., G. A. Skochko, and D. C. Pevear. The mechanism of action of pleconaril against human picornaviruses. Submitted for publication.
54. Weiner, L. B., H. A. Rotbart, D. L. Gilbert, F. G. Hayden, J. H. Mynhardt, D. E. Dwyer, H. Trocha, J. M. Rogers, and M. A. McKinlay. 1997. Treatment of enterovirus meningitis with pleconaril (VP 63843), an antipicornaviral agent, abstr. LB-27, p. 14. In Program addendum of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
55. Woods, M. G., G. D. Diana, M. C. Rogge, M. J. Otto, F. J. Dutko, and M. A. McKinlay. 1989. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 33:2069-2074.